Aardvark Therapeutics (AARD) Common Equity (2024 - 2026)
Aardvark Therapeutics (AARD) posted Common Equity of $87.0 million for Q1 2026, down 18.42% sequentially from $106.6 million in Q4 2025, and down 42.27% YoY from $150.7 million in Q1 2025.
Aardvark Therapeutics (AARD) Common Equity (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Common Equity for 3 years, with the latest figure at $87.0 million in Q1 2026.
- Quarterly Common Equity fell 42.27% year-over-year to $87.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $87.0 million (down 42.27% YoY) and the FY2025 annual result came in at $106.6 million, up 295.14% from the prior year.
- Common Equity retreated to $87.0 million in Q1 2026 per AARD's latest filing, from $106.6 million in the prior quarter.
- Over five years, Common Equity peaked at $150.7 million in Q1 2025 and troughed at -$54.6 million in Q4 2024.
- A 3-year average of $47.1 million and a median of $87.0 million in 2026 frame the typical range for Common Equity.
- The sharpest annual moves came in 2025 and 2026: Common Equity jumped 508.25% in 2025, then tumbled 42.27% in 2026.
- Over 3 years, Common Equity stood at -$54.6 million in 2024, then jumped by 295.14% to $106.6 million in 2025, then fell by 18.42% to $87.0 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $87.0 million, $106.6 million, and $122.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Aardvark Therapeutics | 127.36 Mn | 53.44 Mn | - | 74.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.80 Mn |
| Mar 31, 2026 | 86.99 Mn |
| Dec 31, 2025 | 106.63 Mn |
| Sep 30, 2025 | 122.38 Mn |
| Jun 30, 2025 | 136.93 Mn |
| Mar 31, 2025 | 150.69 Mn |
| Dec 31, 2024 | -54.64 Mn |
| Sep 30, 2024 | -46.17 Mn |
| Jun 30, 2024 | -42.31 Mn |
| Mar 31, 2024 | -36.91 Mn |